Literature DB >> 22378549

Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group.

Valentina Svicher1, Claudia Alteri, Marco Montano, Roberta D'Arrigo, Massimo Andreoni, Gioacchino Angarano, Andrea Antinori, Guido Antonelli, Tiziano Allice, Patrizia Bagnarelli, Fausto Baldanti, Ada Bertoli, Marco Borderi, Enzo Boeri, Isabella Bon, Bianca Bruzzone, Anna Paola Callegaro, Maria Rosaria Capobianchi, Giampiero Carosi, Roberto Cauda, Francesca Ceccherini-Silberstein, Massimo Clementi, Antonio Chirianni, Manuela Colafigli, Antonella D'Arminio Monforte, Andrea De Luca, Antonio Di Biagio, Giuseppe Di Nicuolo, Giovanni Di Perri, Massimo Di Pietro, Fabiola Di Santo, Lavinia Fabeni, Giovanni Fadda, Massimo Galli, William Gennari, Valeria Ghisetti, Andrea Giacometti, Caterina Gori, Andrea Gori, Roberto Gulminetti, Francesco Leoncini, Gaetano Maffongelli, Franco Maggiolo, Giuseppe Manca, Franco Gargiulo, Canio Martinelli, Renato Maserati, Francesco Mazzotta, Genny Meini, Valeria Micheli, Laura Monno, Cristina Mussini, Pasquale Narciso, Silvia Nozza, Stefania Paolucci, Giorgio Pal, Saverio Parisi, Giustino Parruti, Angela Rosa Pignataro, Michela Pollicita, Tiziana Quirino, Maria Carla Re, Giuliano Rizzardini, Rosaria Santangelo, Renzo Scaggiante, Gaetana Sterrantino, Ombretta Turriziani, Maria Linda Vatteroni, Laura Vecchi, Claudio Viscoli, Vincenzo Vullo, Maurizio Zazzi, Adriano Lazzarini, Carlo Federico Perno.   

Abstract

OBJECTIVE: The DIVA study is aimed at setting up a standardized genotypic tropism-testing on proviral-DNA for the routine clinical diagnostic-laboratory.
METHODS: Twelve local centres and 5 reference centres (previously cross-validated) were identified. For inter-center validation-procedure, 60 peripheral-blood mononuclear cells (PBMCs) aliquots from 45 HAART-treated patients were randomly chosen for population V3 sequencing on proviral-DNA at local HIV centre and at reference-laboratory. Viral tropism was predicted by Geno2Pheno algorithm (False Positive Rate [FPR] = 20%) as proposed by the European-Guidelines. Quantification of total HIV-1 DNA was based on a method described by Viard (2004).
RESULTS: Quantification of HIV-1 DNA was available for 35/45 (77.8%) samples, and gave a median value of 598 (IQR:252- 1,203) copies/10 PBMCs. A total of 56/60 (93.3%) samples were successfully amplified by both the reference and the local virological centers. The overall concordance of tropism prediction between local and reference centers was 54/56 (96.4%). Results of tropism prediction by local centers were: 33/54 (61.1%) R5 and 21/54 (38.9%) X4/DM.
CONCLUSION: There was high concordance in the genotypic tropism prediction based on proviral DNA among different virological centers throughout Italy. Our results are in line with other European studies, and support the use of genotypic tropism testing on proviral DNA in patients with suppressed plasma HIV-1 RNA candidate to CCR5-antagonist treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22378549

Source DB:  PubMed          Journal:  New Microbiol        ISSN: 1121-7138            Impact factor:   2.479


  11 in total

1.  Issues on results of the external quality assessment for proviral DNA testing of HIV-1 tropism in the Maraviroc Switch collaborative study.

Authors:  Jörg Berg; Christian Paar; Heribert Stoiber; Thomas Klimkait
Journal:  J Clin Microbiol       Date:  2013-12       Impact factor: 5.948

2.  HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations.

Authors:  Cécile Tremblay; Isabelle Hardy; Richard Lalonde; Benoit Trottier; Irina Tsarevsky; Louis-Philippe Vézina; Michel Roger; Mark Wainberg; Jean-Guy Baril
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

3.  Complexity and dynamics of HIV-1 chemokine receptor usage in a multidrug-resistant adolescent.

Authors:  Mariangela Cavarelli; Lara Mainetti; Angela Rosa Pignataro; Alba Bigoloni; Monica Tolazzi; Andrea Galli; Silvia Nozza; Antonella Castagna; Michela Sampaolo; Enzo Boeri; Gabriella Scarlatti
Journal:  AIDS Res Hum Retroviruses       Date:  2014-12       Impact factor: 2.205

4.  Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia.

Authors:  Lavinia Fabeni; Giulia Berno; Valentina Svicher; Francesca Ceccherini-Silberstein; Caterina Gori; Ada Bertoli; Cristina Mussini; Miriam Lichtner; Mauro Zaccarelli; Adriana Ammassari; Carmela Pinnetti; Stefania Cicalini; Claudio Maria Mastroianni; Massimo Andreoni; Andrea Antinori; Carlo Federico Perno; Maria Mercedes Santoro
Journal:  J Clin Microbiol       Date:  2015-07-01       Impact factor: 5.948

5.  Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative study.

Authors:  Elise Tu; Luke C Swenson; Sally Land; Sarah Pett; Sean Emery; Kat Marks; Anthony D Kelleher; Steve Kaye; Rolf Kaiser; Eugene Schuelter; Richard Harrigan
Journal:  J Clin Microbiol       Date:  2013-04-17       Impact factor: 5.948

6.  Phylogenetic analysis of HIV type 1 CRF02_AG in multiple genes in Italian and African patients living in Italy.

Authors:  Stefania Paolucci; Antonio Piralla; Loretta Fiorina; Roberto Gulminetti; Stefano Novati; Alessia Lai; Fausto Baldanti
Journal:  AIDS Res Hum Retroviruses       Date:  2014-07-10       Impact factor: 2.205

7.  Determination of HIV-1 coreceptor tropism using proviral DNA in women before and after viral suppression.

Authors:  Russell E Baumann; Amy A Rogers; Hasnah B Hamdan; Harold Burger; Barbara Weiser; Wei Gao; Kathryn Anastos; Mary Young; William A Meyer; Rick L Pesano; Ron M Kagan
Journal:  AIDS Res Ther       Date:  2015-04-18       Impact factor: 2.250

8.  Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group.

Authors:  V Svicher; C Alteri; M Montano; A Nori; R D'Arrigo; M Andreoni; G Angarano; A Antinori; G Antonelli; T Allice; P Bagnarelli; F Baldanti; A Bertoli; M Borderi; E Boeri; I Bon; B Bruzzone; R Barresi; S Calderisi; A P Callegaro; M R Capobianchi; F Gargiulo; F Castelli; R Cauda; F Ceccherini-Silberstein; M Clementi; A Chirianni; M Colafigli; A D'Arminio Monforte; A De Luca; A Di Biagio; G Di Nicuolo; G Di Perri; F Di Santo; G Fadda; M Galli; W Gennari; V Ghisetti; A Costantini; A Gori; R Gulminetti; F Leoncini; G Maffongelli; F Maggiolo; R Maserati; F Mazzotta; G Meini; V Micheli; L Monno; C Mussini; S Nozza; S Paolucci; G Palù; S Parisi; G Parruti; A R Pignataro; T Quirino; M C Re; G Rizzardini; M Sanguinetti; R Santangelo; R Scaggiante; G Sterrantino; O Turriziani; M L Vatteroni; C Viscoli; V Vullo; M Zazzi; A Lazzarin; C F Perno
Journal:  Infection       Date:  2013-10-22       Impact factor: 3.553

9.  Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial.

Authors:  Stefano Rusconi; Paola Vitiello; Fulvio Adorni; Elisa Colella; Emanuele Focà; Amedeo Capetti; Paola Meraviglia; Clara Abeli; Stefano Bonora; Marco D'Annunzio; Antonio Di Biagio; Massimo Di Pietro; Luca Butini; Giancarlo Orofino; Manuela Colafigli; Gabriella d'Ettorre; Daniela Francisci; Giustino Parruti; Alessandro Soria; Anna Rita Buonomini; Chiara Tommasi; Silvia Mosti; Francesca Bai; Silvia Di Nardo Stuppino; Manuela Morosi; Marco Montano; Pamela Tau; Esther Merlini; Giulia Marchetti
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

10.  HIV-1 tropism: a comparison between RNA and proviral DNA in routine clinical samples from Chilean patients.

Authors:  Pablo Ferrer; Luisa Montecinos; Mario Tello; Rocio Tordecilla; Consuelo Rodríguez; Marcela Ferrés; Carlos M Pérez; Carlos Beltrán; Maria A Guzmán; Alejandro Afani
Journal:  Virol J       Date:  2013-10-28       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.